Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients

International Immunology

Volumn 18, Issue 11, 2006, Pages 1591-1602

  Oldford, Sharon A ^a   Robb, J Desmond ^a   Codner, Dianne ^a   Gadag, Veeresh ^a   Watson, Peter H ^b   Drover, Sheila ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ESTROGEN RECEPTOR ALPHA; GAMMA INTERFERON; HLA DM ANTIGEN; HLA DR ANTIGEN; HORMONE; INTERLEUKIN 12; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; ONSET AGE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; TH1 CELL; TUMOR CELL;

BREAST NEOPLASMS; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HLA-D ANTIGENS; HLA-DR ANTIGENS; HUMANS; TH1 CELLS;

EID: 33750219785     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxl092     Document Type: Article

References (50)

1. Pardoll, D. M. and Topalian, S. L. 1998. The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol. 10:588.
2. Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D. and Levitsky, H. 1998. The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188:2357.
3. Moller, P., Mattfeldt, T., Gross, C. et al. 1989. Expression of HLA-A, -B, -C, -DR, -DP, -DQ, and of HLA-D-associated invariant chain (Ii) in non-neoplastic mammary epithelium, fibroadenoma, adenoma, and carcinoma of the breast. Am. J. Pathol. 135:73.
4. Tabibzadeh, S. S., Sivarajah, A., Carpenter, D., Ohlsson-Wilhelm, B. M. and Satyaswaroop, P. G. 1990. Modulation of HLA-DR expression in epithelial cells by interleukin 1 and estradiol-17 beta. J. Clin. Endocrinol. Metab 71:740.
5. Bernard, D. J., Maurizis, J. C., Chassagne, J., Chollet, P. and Plagne, R. 1986. Effect of prolactin on class II HLA antigen expression by MCF7 cell line. Anticancer Res. 6:79.
6. Gastl, G., Marth, C., Leiter, E. et al. 1985. Effects of human recombinant alpha 2 arg-interferon and gamma-interferon on human breast cancer cell lines: Dissociation of antiproliferative activity and induction of HLA-DR antigen expression. Cancer Res. 45:2957.
7. Jabrane-Ferrat, N., Faille, A., Loiseau, P., Poirier, O., Charron, D. and Calvo, F. 1990. Effect of gamma interferon on HLA class-I and -II transcription and protein expression in human breast adenocarcinoma cell lines. Int. J. Cancer 45:1169.
8. Sedlak, J., Speiser, P., Zeillinger, R. et al. 1992. Cytokine (IFN-alpha, IFN-gamma, IL-1-alpha, TNF-alpha)-induced modulation of HLA cell surface expression in human breast cancer cell lines. Neoplasma 39:269.
9. Dadmarz, R., Sgagias, M. K., Rosenberg, S. A. and Schwartzentruber, D. J. 1995. CD4+ T lymphocytes infiltrating human breast cancer recognize autologous tumor in an MHC-class-II restricted fashion. Cancer Immunol. Immunother. 40:1.
10. Armstrong, T. D., Clements, V. K. and Ostrand-Rosenberg, S. 1998. Class II-transfected tumor cells directly present endogenous antigen to CD4+ T cells in vitro and are APCs for tumor-encoded antigens in vivo. J. Immunother. 21:218.
11. Meazza, R., Comes, A., Orengo, A. M., Ferrini, S. and Accolla, R. S. 2003. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells. Eur. J. Immunol. 33:1183.
12. Whitwell, H. L., Hughes, H. P., Moore, M. and Ahmed, A. 1984. Expression of major histocompatibility antigens and leucocyte infiltration in benign and malignant human breast disease. Br. J. Cancer 49:161.
13. Gottlinger, H. G., Rieber, P., Gokel, J. M., Lohe, K. J. and Riethmuller, G. 1985. Infiltrating mononuclear cells in human breast carcinoma: Predominance of T4+ monocytic cells in the tumor stroma. Int. J. Cancer 35:199.
14. Zuk, J. A. andWalker, R. A. 1987. Immunohistochemical analysis of HLA antigens and mononuclear infiltrates of benign and malignant breast. J. Pathol. 152:275.
15. Concha, A., Ruiz-Cabello, F., Cabrera, T., Nogales, F., Collado, A. and Garrido, F. 1995. Different patterns of HLA-DR antigen expression in normal epithelium, hyperplastic and neoplastic malignant lesions of the breast. Eur. J. Immunogenet. 22:299.
16. Zuk, J. A. and Walker, R. A. 1988. HLA class II sublocus expression in benign and malignant breast epithelium. J. Pathol. 155:301.
17. Brunner, C. A., Gokel, J. M., Riethmuller G. and Johnson, J. P. 1991. Expression of HLA-D subloci DR and DQ by breast carcinomas is correlated with distinct parameters of favourable prognosis. Eur. J. Cancer 27:411.
18. Wintzer, H. O., Benzing, M. and von Kleist, S. 1990. Lacking prognostic significance of beta 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas. Br. J. Cancer 62:289.
19. Sheen-Chen, S. M., Chou, F. F., Eng, H. L. and Chen, W. J. 1994. An evaluation of the prognostic significance of HLA-DR expression in axillary-node-negative breast cancer. Surgery 116:510.
20. Maiorana, A., Cesinaro, A. M., Fano, R. A. and Collina, G. 1995. Expression of MHC class I and class II antigens in primary breast carcinomas and synchronous nodal metastases. Clin. Exp. Metastasis 13:43.
21. Redondo, M., Garcia, J., Villar, E. et al. 2003. Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis. Hum. Pathol. 34:1283.
22. Roche, P. A., Marks, M. S. and Cresswell, P. 1991. Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain. Nature 354:392.
23. Denzin, L. K. and Cresswell, P. 1995. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading. Cell 82:155.
24. Koretz, K., Moldenhauer, G., Majdic, O. and Moller, P. 1989. Correlation of HLA-D/Ii antigen expression in breast carcinoma with local lymphohistiocytic infiltration reveals considerable dysregulation in a subset of tumors. Int. J. Cancer 44:816.
25. Ishigami, S., Natsugoe, S., Tokuda, K. et al. 2001. Invariant chain expression in gastric cancer. Cancer Lett. 168:87.
26. Jiang, Z., Xu, M., Savas, L., LeClair, P. and Banner, B. F. 1999. Invariant chain expression in colon neoplasms. Virchows Arch. 435:32.
27. Armstrong, T. D., Clements, V. K. and Ostrand-Rosenberg, S. 1998. MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes. J. Immunol. 160:661.
28. Oldford, S. A., Robb, J. D.,Watson, P. H. and Drover, S. 2004. HLA-DRB alleles are differentially expressed by tumor cells in breast carcinoma. Int. J. Cancer 112:399.
29. Elston, C. W. and Ellis, I. O. 1991. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403.
30. Greene, F. L., Page, D. L., Fleming, I. D. et al. eds. 2005. AJCC Cancer Staging Manual, 6 edn. Springer-Verlag, New York.
31. Jimenez, R. E., Wallis, T., Tabasczka, P. and Visscher, D. W. 2000. Determination of Her-2/Neu status in breast carcinoma: Comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod. Pathol. 13:37.
32. Paterno, G. D., Mercer, F. C., Chayter, J. J., Yang, X., Robb, J. D. and Gillespie, L. L. 1998. Molecular cloning of human er1 cDNA and its differential expression in breast tumours and tumour-derived cell lines. Gene 222:77.
33. Kotake, S., Schumacher, H. R., Jr, and Wilder, R. L. 1996. A simple nested RT-PCR method for quantitation of the relative amounts of multiple cytokine mRNAs in small tissue samples. J. Immunol. Methods 199:193.
34. Min, Y. G., Lee, C. H., Rhee, C. S., Hong, S. K. and Kwon, S. H. 1999. Increased expression of IL-4, IL-5, IFN-gamma, IL-6, IL-8, and TGF-beta mRNAs in maxillary mucosa of patients with chronic sinusitis. Am. J. Rhinol. 13:339.
35. Reith, W., LeibundGut-Landmann, S. and Waldburger, J. M. 2005. Regulation of MHC class II gene expression by the class II transactivator. Nat. Rev. Immunol. 5:793.
36. Tai, A. K., Zhou, G., Chau, K. and Ono, S. J. 1999. Cis-element dependence and occupancy of the human invariant chain promoter in CIITA-dependent and -independent transcription. Mol. Immunol. 36:447.
37. Westerheide, S. D., Louis-Plence, P., Ping, D., He, X. F. and Boss, J. M. 1997. HLA-DMA and HLA-DMB gene expression functions through the conserved S-X-Y region. J. Immunol. 158:4812.
38. Spurrell, D. R., Oldford, S. A., Frost, T. et al. 2004. Discordant expression of HLA class II-associated co-chaperones and HLA-DRB alleles in cultured fibroblast-like synoviocytes. Hum. Immunol. 65:1516.
39. Campoli, M., Chang, C. C., Oldford, S. A., Edgecombe, A. D., Drover, S. and Ferrone, S. 2004. HLA antigen changes in malignant tumors of mammary epithelial origin: Molecular mechanisms and clinical implications. Breast Dis. 20:105.
40. Adamski, J., Ma, Z., Nozell, S. and Benveniste, E. N. 2004. 17beta-Estradiol inhibits class II major histocompatibility complex (MHC) expression: Influence on histone modifications and cbp recruitment to the class II MHC promoter. Mol. Endocrinol. 18:1963.
41. Adamski, J. and Benveniste, E. N. 2005. 17beta-Estradiol activation of the c-Jun N-terminal kinase pathway leads to down-regulation of class II major histocompatibility complex expression. Mol. Endocrinol. 19:113.
42. Sloan, V. S., Cameron, P., Porter, G. et al. 1995. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 375:802.
43. Riberdy, J. M., Newcomb, J. R., Surman, M. J., Barbosa, J. A. and Cresswell, P. 1992. HLA-DR molecules froman antigen-processing mutant cell line are associated with invariant chain peptides. Nature 360:474.
44. Chaturvedi, P., Hengeveld, R., Zechel, M. A., Lee-Chan, E. and Singh, B. 2000. The functional role of class II-associated invariant chain peptide (CLIP) in its ability to variably modulate immune responses. Int. Immunol. 12:757.
45. Rohn, T. A., Boes, M., Wolters, D. et al. 2004. Upregulation of the CLIP self peptide on mature dendritic cells antagonizes T helper type 1 polarization. Nat. Immunol. 5:909.
46. Thompson, J. A., Dissanayake, S. K., Ksander, B. R., Knutson, K. L., Disis, M. L. and Ostrand-Rosenberg, S. 2006. Tumor cells transduced with the MHC class II transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Res. 66:1147.
47. Chamuleau, M. E., Souwer, Y., Van Ham, S. M. et al. 2004. Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res. 64: 5546.
48. Marth, C., Fiegl, H., Zeimet, A. G. et al. 2004. Interferon-gamma expression is an independent prognostic factor in ovarian cancer. Am. J. Obstet. Gynecol. 191:1598.
49. Madjd, Z., Spendlove, I., Pinder, S. E., Ellis, I. O. and Durrant, L. G. 2005. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int. J. Cancer 117:248.
50. Jimenez, P., Canton, J., Collado, A. et al. 1999. Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. Int. J. Cancer 83:91.